Latest:
Suzanne Beauchene on the Provenge Treatment Process
Suzanne Beauchene from Seattle Cancer Care Alliance Discusses the Provenge Treatment Process from Start to Finish
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Suzanne George, MD
Latest:
Dr. George on the Importance of Collaboration in the Treatment of Uterine Sarcomas
Suzanne George, MD, director of Clinical Research, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, and an associate professor of medicine, Harvard Medical School, discusses the importance of collaboration in the treatment of patients with uterine sarcoma.
Suzanne L. Topalian, MD
Latest:
Dr. Topalian on the Immunosuppressive Tumor Microenvironment of Nasopharyngeal Cancer
Suzanne L. Topalian, MD, director, Melanoma Program, professor of Surgery and Oncology, Johns Hopkins Medicine, discusses the immunosuppressive microenvironment of nasopharyngeal cancer.
Sylvia C. Eisele, MD, PhD
Latest:
Blocking the PD-1/PD-L1 Signaling Pathway in Malignant Glioma: Current and Future Perspectives
Blockade of the PD-1/PD-L1 pathway is a novel and attractive treatment approach to many cancers, including malignant glioma, because of its potential to restore anti-tumor immunity.
Tahir Latif, MD
Latest:
Dr. Tahir Latif on Lower Male Survival Rates in Diffuse Large B-cell Lymphoma
Tahir Latif, MD, associate professor of Medicine, interim chief, Division of Hematology Oncology, director, Infusion Services University of Cincinnati Cancer Institute, discusses differences in male survival rates versus female among patients with diffuse large B-cell lymphoma (DLBCL).
Taimur Aslam
Latest:
Protecting privacy in the electronic era: HIPAA and HITECH mandates
In 1890, Louise Brandeis and Samuel Warren published �¢ï¿½ï¿½The Right to Privacy�¢ï¿½ï¿½ in the Harvard Law Review, indicating private individuals were being injured by the invasions of modern-day technology
Takayuki Yoshino, MD
Latest:
Dr. Yoshino Discusses the Safety Profile of TAS-102
Takayuki Yoshino, MD, medical oncologist, National Cancer Center Hospital East, Chiba, Japan, discusses the safety profile of TAS-102 as seen in a phase III study of the agent versus placebo, with best supportive care, in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies.
Talia Golan, MD
Latest:
Dr. Golan on the Phase III POLO Trial in BRCA-Mutant Pancreatic Cancer
Talia Golan, MD, head of Sheba Pancreatic Cancer Center, discusses the results of the phase III POLO trial, which evaluated maintenance olaparib compared with placebo among patients with germline BRCA-mutated metastatic pancreatic cancer.